NCT02974738 is a Phase 1 clinical trial of Belzutifan in Advanced Solid Tumors, sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Who is sponsoring NCT02974738?

NCT02974738 is sponsored by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What drugs are being tested in NCT02974738?

Interventions in NCT02974738: Belzutifan.

What condition does NCT02974738 study?

NCT02974738 studies Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, ccRCC, RCC, Clear Cell Adenocarcinoma, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Carcinoma, Clear Cell Adenocarcinoma, Glioblastoma, Glioblastoma, Adult, GBM, Glioblastoma Multiforme.

Is NCT02974738 still recruiting?

NCT02974738 is currently active, enrolled. Last updated 10 July 2025.

Last reviewed 2025-07-10 · How we verify

NCT02974738

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Active, enrolled Phase 1 Last updated 10 July 2025

What this trial tests

Phase 1 trial testing Belzutifan in Advanced Solid Tumors in 120 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 December 2016

Primary endpoint
12 January 2018

14 April 2027

Quick facts

Lead sponsor	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	7 December 2016
Primary completion	12 January 2018
Estimated completion	14 April 2027

Drugs / interventions tested

Belzutifan (BELZUTIFAN) — full drug profile →

Conditions studied

Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Solid Tumor — all drugs for Solid Tumor →
Solid Carcinoma — all drugs for Solid Carcinoma →
Solid Tumor, Adult — all drugs for Solid Tumor, Adult →

Sponsor

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors or Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.
Wen PY, Weller M, Lee EQ, Alexander BM, et al · · 2020 · cited 908× · PMID 32328653 · DOI 10.1093/neuonc/noaa106
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge.
Nedeljković M, Damjanović A. · · 2019 · cited 576× · PMID 31443516 · DOI 10.3390/cells8090957
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.
Choueiri TK, Bauer TM, Papadopoulos KP, Plimack ER, et al · · 2021 · cited 229× · PMID 33888901 · DOI 10.1038/s41591-021-01324-7
Tumor microenvironment in glioblastoma: Current and emerging concepts.
Sharma P, Aaroe A, Liang J, Puduvalli VK. · · 2023 · cited 202× · PMID 36968288 · DOI 10.1093/noajnl/vdad009
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman SJ, Koh MY. · · 2022 · cited 192× · PMID 34743924 · DOI 10.1016/j.trecan.2021.10.004
Glioma stem cells and their roles within the hypoxic tumor microenvironment.
Boyd NH, Tran AN, Bernstock JD, Etminan T, et al · · 2021 · cited 174× · PMID 33391498 · DOI 10.7150/thno.41692
Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma.
Sharma R, Kadife E, Myers M, Kannourakis G, et al · · 2021 · cited 120× · PMID 34099013 · DOI 10.1186/s13046-021-01961-3
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J, Brave MH, Weinstock C, Mehta GU, et al · · 2022 · cited 112× · PMID 35727604 · DOI 10.1158/1078-0432.ccr-22-1054

Verify or expand the search:

Other trials of Belzutifan

Trials testing the same drug.

NCT07489495 — A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-0 · Phase 3 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
NCT07023432 — Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE · Phase 2 · not yet recruiting
NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting

Other recruiting trials for Advanced Solid Tumors

Currently open trials in the same condition.

NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Trials by the same sponsor.

NCT03634540 — A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinom · Phase 2 · active not recruiting
NCT03401788 — A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Ce · Phase 2 · active not recruiting
NCT03445169 — A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets · Phase 1 · completed
NCT03108066 — MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) · Phase 2 · completed
NCT02293980 — A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-00 · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02974738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 10 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02974738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing